Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Report Overview
Female sexual dysfunction (FSD) is an umbrella term that encompasses disorders of sexual desire, orgasm, arousal, and sexual pain that result in significant personal distress. FSD is a multifactorial, progressive problem that can occur at any stage of life. It is a complex neurovascular phenomenon that is under the control of psychological, neurovascular, and hormonal factors.
| Key Mechanisms of Action (Marketed) | · Receptor Agonist
· Enzyme Inhibitor · Receptor Antagonist |
| Key Molecule Types (Marketed) | · Small Molecule
· Biologic |
| Key Routes of Administration (Marketed) | · Oral
· Injection · Suppository · Inhalational · Topical |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Female Sexual Dysfunction Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for female sexual dysfunction.
The report also provides actionable insights into the clinical and commercial landscapes of female sexual dysfunction drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
| Key Mechanisms of Action (Pipeline) | · Receptor Agonist
· Receptor Antagonist · Enzyme Inhibitor · Transporter Inhibitor |
| Key Molecule Types (Pipeline) | · Biologic
· Small Molecule |
| Key Routes of Administration (Pipeline) | · Injection
· Oral · Suppository · Topical · Inhalational |
| Top Sponsors (Marketed and Pipeline Drugs) | · Shahid Beheshti University of Medical Sciences
· Tabriz University of Medical Sciences · Mashhad University of Medical Sciences · Ahvaz Jundishapur University of Medical Sciences · Tehran University of Medical Sciences |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Female Sexual Dysfunction Marketed Drugs Market Segmentation by Mechanisms of Action
The key MoA of the marketed drugs for female sexual dysfunction include receptor agonists, receptor antagonists, and enzyme inhibitors. Most of the marketed drugs followed receptor agonist MoA in 2023 in the female sexual dysfunction market.
Female Sexual Dysfunction Marketed Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report for More MoA insights into the Female Sexual Dysfunction Marketed Drugs
Female Sexual Dysfunction Marketed Drugs Market Segmentation by Routes of Administration
The key RoA of female sexual dysfunction marketed drugs include oral, injection, suppository, inhalational, and topical. In 2023, most marketed drugs that were available for female sexual dysfunction were vaginal suppositories, followed by oral therapies.
Female Sexual Dysfunction Marketed Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report for More RoA insights into the Female Sexual Dysfunction Marketed Drugs
Female Sexual Dysfunction Marketed Drugs Market Segmentation by Molecule Types
The key molecule types of female sexual dysfunction marketed drugs are small molecule and biologic. In 2023, the leading molecule type was small molecule.
Female Sexual Dysfunction Marketed Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report for More Molecule Types Insights into the Female Sexual Dysfunction Marketed Drugs
Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the female sexual dysfunction pipeline mainly includes receptor agonists, receptor antagonists, enzyme activators, and transport inhibitors. Most of the pipeline drugs undergoing development for female sexual dysfunction followed receptor agonist MoA in 2023.
Female Sexual Dysfunction Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report for More MoA Insights into the Female Sexual Dysfunction Pipeline Drugs Market
Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Routes of Administration
The key RoA of the drugs in the female sexual dysfunction pipeline mainly includes injection, oral, inhalational, topical, and suppository. In 2023, most pipeline drugs that were under development for female sexual dysfunction were oral therapies.
Female Sexual Dysfunction Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report for More RoA Insights into the Female Sexual Dysfunction Pipeline Drugs Market
Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types of female sexual dysfunction pipeline drugs are biologic and small molecule. In 2023, the leading molecule type for female sexual dysfunction pipeline drugs was small molecule.
Premature Labor Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report for More Molecule Type Insights into the Female Sexual Dysfunction Pipeline Drugs Market
Female Sexual Dysfunction Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the female sexual dysfunction marketed and pipeline drugs market are:
- Shahid Beheshti University of Medical Sciences
- Tabriz University of Medical Sciences
- Mashhad University of Medical Sciences
- Ahvaz Jundishapur University of Medical Sciences
- Tehran University of Medical Sciences
Shahid Beheshti University of Medical Sciences sponsored the highest number of trials in 2023.
Female Sexual Dysfunction Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Sponsor Insights into the Female Sexual Dysfunction Marketed and Pipeline Drugs Market
Segments Covered in the Report
Female Sexual Dysfunction Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Enzyme Inhibitor
- Receptor Antagonist
Female Sexual Dysfunction Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Biologic
Female Sexual Dysfunction Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Oral
- Injection
- Suppository
- Inhalational
- Topical
Female Sexual Dysfunction Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonist
- Receptor Antagonist
- Enzyme Inhibitor
- Transporter Inhibitor
Female Sexual Dysfunction Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologic
- Small Molecule
Female Sexual Dysfunction Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Suppository
- Topical
- Inhalational
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the FSD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global FSD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for female sexual dysfunction marketed drugs in 2023?
Most of the drugs followed receptor agonist MoA in 2023 in the female sexual dysfunction drugs market.
-
Which was the leading molecule type for female sexual dysfunction marketed drugs in 2023?
In 2023, majority of the marketed drugs for female sexual dysfunction were small molecules.
-
Which was the leading molecule type for female sexual dysfunction pipeline drugs in 2023?
In 2023, most of the drugs in development for female sexual dysfunction were small molecules.
-
Who are the top sponsors in the female sexual dysfunction marketed and pipeline drugs market?
A few of the top sponsors in the female sexual dysfunction marketed and pipeline drugs market are Shahid Beheshti University of Medical Sciences, Tabriz University of Medical Sciences, Mashhad University of Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, and Tehran University of Medical Sciences.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Female Sexual Dysfunction reports